Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma
Matthew S Davids, Gottfried von Keudell, Craig A Portell, Jonathon B Cohen, David C Fisher, Francine Foss, Andrew W Roberts, John F Seymour, Rod A Humerickhouse, Constantine S Tam
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018
Venetoclax is being developed in collaboration between AbbVie and Genentech-Roche. AbbVie, Genentech-Roche, and Janssen Pharmaceuticals provided financial support for the venetoclax clinical studies. AbbVie and Genentech-Roche were involved in the writing, review, and approval of this correspondence. Medical writing and support were provided by Ryan J. Bourgo, PhD, and Sharanya Ford, PhD, of AbbVie.